کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2164167 1091483 2008 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Development of novel agents and combinations for renal carcinoma
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Development of novel agents and combinations for renal carcinoma
چکیده انگلیسی

Based on a better understanding of the pathogenesis of renal carcinoma, the last 5 years has witnessed a rapid transition of novel agents from the bench to the bedside. Multiple new drugs have already been approved for standard use including sunitinib, sorafenib, and temsirolimus with additional agents including everolimus, bevacizumab, and pazopanib under review by the regulatory agencies. This review will highlight the clinical data, which support the use of these novel agents and highlight current approaches exploring combination therapy.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Update on Cancer Therapeutics - Volume 3, Issue 2, December 2008, Pages 97–103
نویسندگان
, , , , , , ,